Genitourinary Cancers

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Adjuvant durvalumab plus tremelimumab significantly improved DFS vs active monitoring in both high- and intermediate-risk resected RCC.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

OncLive announced the 2026 Giants of Cancer Care winners.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.

Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.

Nivolumab plus cabozantinib was safe and active for the real-world frontline treatment of patients with advanced RCC.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Fecal microbiota transplantation extended median PFS with first-line pembrolizumab plus axitinib in metastatic RCC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Darlifarnib plus cabozantinib showed preliminary activity and safety across dose levels in cabozantinib-treated ccRCC.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Cabozantinib was active with no new safety signals in second-line advanced RCC after treatment with frontline checkpoint inhibitor–based therapy.

Akshit Chitkara, MD, discusses outcomes with IO doublet therapy by dedifferentiation status and histologic grade in ccRCC.

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

Toni K. Choueiri, MD, discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study.